Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Texas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Texas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Texas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Lori Coors (NPI 1427057223)

Field	Value
Entity Type	Individual
Organization	Lori Coors
Address	9600 N. Central Expressway
City	Dallas
State	TX
ZIP	75231
Taxonomy	Ophthalmology Physician
NPI Enumerated	July 14, 2005

Payer Source	Total Paid
Medicare	$5.2M
Medicaid	$0

Key Findings

Practice is heavily retina- and injection-focused: the largest revenue drivers are intravitreal drug and procedure codes — J0178 (2.9M revenue, 55.8% of Medicare revenue), J2777 (1.3M revenue, 25.1%), and 67028 (237.5K revenue, 4.6%) — and diagnostic retinal imaging codes such as 92134 ($137.8K) and angiography 92235 ($17.6K) also appear on the list. These code-level patterns indicate day-to-day operations centered on high-volume anti‑VEGF and retina follow-up care rather than broad primary ophthalmology services.

Revenue is highly concentrated: the precomputed top‑3 Medicare codes account for 85.5% of this provider's total Medicare revenue. That concentration (anchored in a few drug/procedure codes) suggests the practice’s financial performance on Medicare is materially dependent on continued reimbursement and utilization of those specific intravitreal therapies and associated injection visits.

This provider is effectively single‑payer at the state level: Total Medicare revenue is $5.2M while Medicaid activity is none, meaning there is no Medicaid billing on file. The absence of Medicaid revenue leaves the practice exposed to policy or reimbursement shifts in Medicare without a Medicaid revenue buffer.

Competitive standing on anti‑VEGF use is strong for certain agents: J0178 ranks #58 of 3204 providers nationally (98th percentile) and is described as notably above typical national volume, positioning this provider as a national high‑volume user of aflibercept. By contrast, J2777 ranks #136 of 2039 (93th percentile) and is characterized as typical/unremarkable volume for that code, so faricimab use is sizable but not as disproportionate relative to peers.

Diagnostic and follow‑up throughput is an outlier: 92014 (established patient comprehensive exam) and 92134 (retinal imaging) are both flagged as extreme outliers at the national level (92014: 2.3K claims, $189.8K revenue; 92134: 4.6K claims, $137.8K revenue). These extreme volumes for office visits and OCT interpretation are consistent with a high‑throughput intravitreal injection practice model that combines frequent follow‑up exams and imaging with injection visits.

Surgical retina services are present at above‑typical volumes: pars plana vitrectomy and related surgical codes such as 67042 ($73.2K revenue, ranks #41 of 1087 nationally, 96th percentile/notably above typical) and 67036 ($35.6K revenue) indicate the provider performs vitreoretinal procedures in addition to injections. The presence of both injection and operative codes suggests a vertically integrated retina service line rather than purely office‑based injection work.

The provider’s drug mix shows dominance of aflibercept with meaningful use of newer agents and some biosimilar activity: J0178 (aflibercept) accounts for $2.9M, J2777 (faricimab) for $1.3M, while Q5128 (ranibizumab biosimilar) contributed $87.8K and ranks #245 of 373 (34th percentile) — indicating some use of biosimilars but at much lower volumes relative to aflibercept and faricimab. Lower national ranks for J2778 (ranibizumab) and modest Q5128 uptake suggest limited reliance on older ranibizumab branded product and selective biosimilar adoption.

Long tenure but payer concentration risk: the NPI was enumerated on 2005-07-14 (~21 years ago), indicating an established practice with long operating history. Combined with the heavy Medicare concentration ($5.2M Medicare revenue and no Medicaid billing on file) and reliance on a small set of high‑revenue drug/procedure codes, this profile points to an established retina practice that could be sensitive to changes in Medicare drug coverage, reimbursement, or utilization patterns.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

22 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	4,180	$690	$2.9M
J2777	Injection, faricimab‑svoa, 0.1 mg	44,820	$30	$1.3M
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,610	$90	$237.5K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	2,260	$80	$189.8K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	4,590	$30	$137.8K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	400	$220	$87.8K
67042	In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina…	80	$900	$73.2K
92012	For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any…	850	$70	$55.1K
67036	The provider removes vitreous fluid from the eye to access the posterior segment of the eye and introduce surgical instruments through incisions in the pars plana.	50	$700	$35.6K
92004	The provider performs a comprehensive level ophthalmological evaluation of a new patient and initiates a diagnostic and treatment program for one or more visits.	330	$110	$34.6K

Showing 1–10 of 22

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 22 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Texas Distribution

Lori Coors — 7 of 22 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Texas

Full comparison — all codes billed, vs. state median

22 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	6	210	610	$690	$694.9K
J2777	12	140	7,470	$30	$479.2K
J2778	82	80	630	$180	$345.3K
Q5128	42	50	770	$220	$263.7K
67028	14	290	510	$90	$73K
67042	8	90	20	$1,150	$41.3K
J7312	19	40	200	$150	$40.8K
67036	11	70	20	$1,000	$29.1K
67108	56	60	20	$1,170	$28.1K
67039	9	20	20	$1,160	$25.6K

Showing 1–10 of 22

Related Providers

Other providers that share a Tax Identification Number (TIN) with Lori Coors, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ashkan Abbey	TX	Ophthalmology Physician	$6.4M	$0
Ivan Castillo-salazar	TX	Ophthalmology Physician	$4.7M	$0
Andrew Mcclellan	TX	Ophthalmology Physician	$4.5M	$0
Wayne Solley	TX	Ophthalmology Physician	$4M	$0
Christopher Fuller	TX	Ophthalmology Physician	$3.6M	$0
Timothy Fuller	TX	Ophthalmology Physician	$3.5M	$0
Robert Wang	TX	Ophthalmology Physician	$3.5M	$0
Patrick Williams	TX	Ophthalmology Physician	$2.8M	$0
Nikisha Kothari	TX	Ophthalmology Physician	$2.4M	$0
Diana Laura	TX	Ophthalmology Physician	$2.3M	$0

Nearby Providers

Other providers in the same ZIP code as Lori Coors, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dallas Independent School District	TX	Local Education Agency (LEA)	$0	$22.6M
North Star Home Health Care Inc	TX	Personal Care Attendant	$0	$10.8M
Ophthalmology Surgery Center Of Dallas, LLC	TX	Ambulatory Surgical Clinic/Center	$8.3M	$134.6K
Deborah Chong	TX	Ophthalmology Physician	$2.3M	$0
Morgan Click	TX	Family Nurse Practitioner	$2.1M	$0
Russell Lam	TX	Vascular Surgery Physician	$2M	$0
Center For Molecular Imaging Limited Partnership	TX	Radiology Clinic/Center	$2M	$0
Gary Fish	TX	Ophthalmology Physician	$2M	$0
Haskell Kirkpatrick	TX	Medical Oncology Physician	$1.8M	$0
Christopher Wright	TX	Rheumatology Physician	$1.4M	$0

Lori Coors — Billing Profile & Reimbursement Data

Sign up for Lori Coors — Billing Profile & Reimbursement Data policy alerts

Lori Coors — Billing Profile & Reimbursement Data

Sign up for Lori Coors — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References